Cell joint agent AFM13 for T-cell lymphoma: approved by FDA Orphan Drug
-
Last Update: 2020-06-22
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Affimed, a clinical oncology treatment company, recently announced that the U.SFood and Drug Administration (FDA) has awarded AFM13, a cell joint used in combination with CD30 and CD16A, for the treatment of peripheral T-cell lymphoma (pTCL, a subtype of T-cell lymphoma)In Phase II clinical trials, Affimed is studying the effectiveness and safety of AFM13 as a single therapy for relapsing or incurable CD30 positive pTCL, and AFM13 has shown good safety and therapeutic resultsAFM13 is a tetravalent, bispecific cell joint that binds specifically to CD30 on tumor cells and CD16A on NK cellsCurrently, AFM13 is being developed for peripheral T-cell lymphoma (pTCL) and other CD30-positive lymphomasThe FDA says drugs that treat fewer than 200,000 patients in the U.Shave the opportunity to apply for orphan drugsTo stimulate research on orphan drugs, the government has mandated that developers receive seven years of market-only patents and a 50 percent tax credit for clinical research and testing
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
